Welcome to our dedicated page for Inmode Ltd. news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on Inmode Ltd. stock.
InMode Ltd. (INMD) delivers innovative radiofrequency-based solutions for minimally invasive aesthetic treatments. This news hub provides investors and medical professionals with essential updates on the company's strategic developments, technological advancements, and market leadership in medical aesthetics.
Access real-time announcements including quarterly earnings, product launch details, regulatory milestones, and partnership agreements. Our curated collection features press releases covering facial/body contouring innovations, clinical study results, and intellectual property developments central to INMD's growth strategy.
Key updates include FDA-cleared device announcements, global expansion initiatives, and R&D breakthroughs in RF energy applications. Bookmark this page for verified information on corporate governance changes, manufacturing updates, and industry conference participation directly from InMode's communications team.
InMode (INMD), a leading global provider of innovative medical technologies, has announced its participation in four major investor conferences during November and December 2024. The company will be represented at the UBS Global Healthcare Conference in California, the Jefferies London Healthcare Conference in the UK, the Canaccord Genuity MedTech Forum in New York, and the Mizuho Medical Device Summit in New York.
CFO Yair Malca and CEO Moshe Mizrahy will participate in fireside chats and one-on-one meetings. Live webcasts will be available for the UBS and Jefferies conferences, scheduled for November 12 and November 20, respectively.
InMode (INMD) reported Q3 2024 GAAP revenue of $130.2 million, including $98.3 million in net sales and $31.9 million from H1 2024 pre-orders, marking a 5.8% increase from Q3 2023. Consumables and service revenue decreased 11% to $15.8 million. The company reported GAAP net income of $51.0 million ($0.65 per share) and non-GAAP net income of $55.0 million ($0.70 per share). Due to macroeconomic challenges, InMode revised its full-year 2024 revenue guidance down to $410-420 million from $430-440 million. Gross margins declined to 82% from 84% in Q3 2023.
InMode (INMD) has secured a preliminary injunction from the U.S. District Court for the Central District of California against sellers of counterfeit Morpheus8 radiofrequency devices and accessories. The court order, issued by Judge Michael Fitzgerald on September 3, 2024, includes asset freezing and listing removals for involved sellers. The company previously obtained a Temporary Restraining Order due to public safety concerns regarding counterfeit medical products. CEO Moshe Mizrahy emphasized the company's zero-tolerance approach to counterfeit products and commitment to public safety. InMode will continue enforcement actions against counterfeit sellers and directs U.S. patients to verify authorized providers through their website.
InMode (Nasdaq: INMD) anticipates releasing its Q3 2024 financial results on October 30, 2024. Preliminary expectations include:
- Q3 revenue between $130.0-$130.1 million, including $31.9 million from H1 2024 pre-orders
- Non-GAAP gross margin of 81-82%
- Revised full-year 2024 revenue guidance to $410-$420 million, down from $430-$440 million
The company fulfilled all pre-orders for two new platforms introduced earlier this year. However, macro-economic factors continue to impact the aesthetics industry. InMode is prioritizing employee safety amid the current situation in Israel and considering relocating some production activities.
A conference call to discuss Q3 results is scheduled for October 30, 2024, at 8:30 a.m. Eastern Time.
InMode (Nasdaq: INMD) announced the departure of three key executives from its North American operations as part of a global reorganization strategy. Shakil Lakhani, President of North America, Dr. Spero Theodorou, Chief Medical Officer, and Dan Wilson, VP of Sales USA, have left the company. InMode has also changed management teams in three European subsidiaries.
This restructuring aligns with InMode's global expansion and penetration into new business verticals, particularly the wellness sector. The role of President of North America will be divided to better manage the company's growth and full pipeline of new platforms. CEO Moshe Mizrahy emphasized that this new structure aims to enhance operational efficiency in North America and build a robust infrastructure for future growth.
InMode (Nasdaq: INMD), a leading global provider of innovative medical technologies, has announced a new share repurchase program of up to 7.68 million ordinary shares. This decision follows the completion of a previous buyback program earlier this year, reflecting the company's ongoing confidence in its long-term outlook.
CEO Moshe Mizrahy emphasized the board's confidence in the company's future, while CFO Yair Malca highlighted InMode's continued profitability and cash generation, even in challenging economic conditions. The company believes there will be no tax implications from the existing program. The repurchases will be funded with available cash and may be commenced, suspended, or discontinued at any time.
InMode (Nasdaq: INMD), a leading global provider of innovative medical technologies, has announced its participation in the 2024 Baird Global Healthcare Conference in New York on September 10, 2024. Key points include:
- CFO Yair Malca will present in-person at a fireside chat moderated by Jeff Johnson, Senior Research Analyst
- The presentation is scheduled for 2:00 pm Eastern Time
- A live webcast of the presentation will be available
- InMode will hold one-on-one investor meetings on the same day
This event provides an opportunity for investors to gain insights into InMode's operations and future prospects. Interested parties can access more information about the event on InMode's investor relations site.
InMode (Nasdaq: INMD), a leading global provider of innovative medical technologies, has announced its participation in two upcoming investor conferences in August 2024. The company will be present at the 9th Annual Needham Virtual MedTech & Diagnostics Conference on August 12, with CEO Moshe Mizrahy and CFO Yair Malca conducting virtual one-on-one meetings. Additionally, CFO Yair Malca will participate in the Canaccord 44th Annual Global Growth Conference on August 14 at 2:00 pm ET, featuring an in-person fireside chat moderated by Caitlin Cronin, Director of MedTech Equity Research, along with meetings. A live webcast of the Canaccord presentation will be available for interested parties.
InMode (INMD) reported Q2 2024 financial results, showing a significant decrease in revenue. Key highlights include:
- GAAP revenue of $86.4 million, down 36.5% year-over-year
- Pro-forma revenue (including pre-orders) of $102.6 million
- GAAP net income of $23.8 million, compared to $55.7 million in Q2 2023
- Non-GAAP diluted EPS of $0.34, down from $0.72 in Q2 2023
The company attributed the challenging quarter to macroeconomic factors and longer production times for new platforms. InMode updated its 2024 outlook, projecting full-year revenue between $430-$440 million, down from previous guidance of $485-$495 million.
InMode (Nasdaq: INMD) has introduced IgniteRF, a revolutionary minimally invasive workstation featuring nine technologies for soft tissue contraction across multiple depths. This platform includes the BodyTite, FaceTite, Morpheus8, and the new QuantumRF family of products, offering a comprehensive suite of radiofrequency solutions for various aesthetic and surgical needs.
The QuantumRF technology deploys fractionated radiofrequency to maximal depths, with two lightweight cannulas: QuantumRF 10 for small, delicate areas and QuantumRF 25 for larger zones. This advancement allows physicians to deliver unprecedented results without invasive surgery. Radiofrequency technology has become the gold standard in skin contraction due to its effectiveness, safety, and minimally invasive nature, stimulating collagen production and promoting tissue remodeling for firmer, more youthful-looking skin.
